Subtype
Malignant Uterine Neoplasm
CI-CAN-00005955Explore in graph →
824 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005955Explore in graph →
Clinical trials
3,291 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (333)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01397877 | GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer(ENDOPIK) | completed | Phase 2 | 24 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT04542356 | Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer | completed | Phase 2 | 60 | Chongqing University Cancer HospitalOTHER | 1 | Sep 6, 2023 |
| clinicaltrials |
| NCT05805358 | Hyperpolarized 13C MRI for Cancer Immunotherapy(DNPSPIO) | unknown | Phase 2 | 90 | Chang Gung Memorial HospitalOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT02112552 | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer | terminated | Phase 2 | 4 | Albert Einstein College of MedicineOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT00794339 | Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer(ACRIN6682) | terminated | Phase 2 | 73 | American College of RadiologyOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04590248 | A Study of Adavosertib as Treatment for Uterine Serous Carcinoma(ADAGIO) | completed | Phase 2 | 109 | AstraZenecaINDUSTRY | 5 | Aug 14, 2023 | clinicaltrials |
| NCT00053794 | Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma | completed | Phase 2 | 17 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00770185 | Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer | completed | Phase 2 | 35 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT03438396 | A Trial of Tisotumab Vedotin in Cervical Cancer | completed | Phase 2 | 102 | Seagen Inc.INDUSTRY | 8 | Jul 25, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT05614453 | Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy(ITTACC) | withdrawn | Phase 2 | 0 | Australia New Zealand Gynaecological Oncology GroupOTHER | 0 | Jun 29, 2023 | clinicaltrials |
| NCT01111461 | Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression | completed | Phase 2 | 133 | Eisai Inc.INDUSTRY | 8 | Jun 22, 2023 | clinicaltrials |
| NCT01689714 | Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma | completed | Phase 2 | 16 | EndocyteINDUSTRY | 0 | Jun 22, 2023 | clinicaltrials |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | terminated | Phase 2 | 1 | pharmaand GmbHINDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05606263 | Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer(GCR-05) | unknown | Phase 2 | 55 | Xi'an Jiaotong UniversityOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT05872724 | Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease) | recruiting | Phase 2 | 32 | Suzhou Municipal HospitalOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT01367002 | Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer | completed | Phase 2 | 61 | Yale UniversityOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT04583254 | Hypofractionated External-beam RadiOtherapy for Intact Cervical Cancer (HEROICC-Trial): A Feasibility Study | recruiting | Phase 2 | 48 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05824494 | Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors | unknown | Phase 2 | 58 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT03642990 | NR in Chemo-induced Peripheral Neuropathy | terminated | Phase 2 | 5 | Donna Hammond, PhDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT03816553 | SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer | completed | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT03073525 | A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers | completed | Phase 2 | 25 | Gradalis, Inc.INDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05799469 | Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 36 | Chongqing University Cancer HospitalOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT00492778 | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer | unknown | Phase 2 | 165 | GOG FoundationNETWORK | 2 | Mar 29, 2023 | clinicaltrials |
| NCT03427411 | M7824 in Subjects With HPV Associated Malignancies | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2023 | clinicaltrials |
| NCT02291055 | A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer | terminated | Phase 1 / Phase 2 | 75 | Advaxis, Inc.INDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT01399658 | Image-Guided Gynecologic Brachytherapy(AMIGO) | completed | Phase 2 | 93 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05419817 | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | withdrawn | Phase 2 | 0 | Haider MahdiOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT02549989 | Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03366480 | A Study to Assess the Efficacy and Safety of ABTL0812(Endolung) | completed | Phase 1 / Phase 2 | 103 | Ability Pharmaceuticals SLINDUSTRY | 1 | Feb 22, 2023 | clinicaltrials |
| NCT02921269 | Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05210270 | HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy(HYACINCT) | not yet recruiting | Phase 1 / Phase 2 | 55 | University of Santo Tomas Hospital, PhilippinesOTHER | 0 | Jan 31, 2023 | clinicaltrials |
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies(SIGN) | completed | Phase 2 | 116 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jan 26, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT04294836 | Curcumin in Advanced Cervical Cancer | withdrawn | Phase 2 | 0 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 0 | Dec 7, 2022 | clinicaltrials |
| NCT01693783 | Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 2 | Nov 8, 2022 | clinicaltrials |
| NCT01097746 | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 2 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | terminated | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05437692 | Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer | unknown | Phase 2 | 19 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05550558 | Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer(CAN-RESPOND) | not yet recruiting | Phase 2 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Sep 28, 2022 | clinicaltrials |
| NCT05557565 | A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer | unknown | Phase 2 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT04398446 | Effect of Hemp-CBD on Patients With CIPN(Coala-T-CBD) | unknown | Phase 2 | 56 | Main Line HealthOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT03394027 | ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Sep 6, 2023source: clinicaltrials